Biologics CDMO Market Size Report, Industry Forecast 2026 to 2035

What Is The Present Market Size Of The Biologics CDMO Market, And At What Annual Growth Rate Is It Expanding?
The biologics cdmo market size has grown rapidly in recent years. It will grow from $24.15 billion in 2025 to $27.56 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rise in biologics research, advancements in cell culture technologies, increasing prevalence of chronic diseases, growth of biosimilar pipelines, government support for biopharma manufacturing.

The biologics cdmo market size is expected to see rapid growth in the next few years. It will grow to $48.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to surge in gene and cell therapy development, adoption of automation and robotics in CDMO processes, expansion of global biologics manufacturing capacity, increasing investment in precision medicine, rising demand for cost-effective biologics. Major trends in the forecast period include expansion of biologics cdmo services, growth in mammalian cell-based production, increase in outsourcing of gene therapy manufacturing, adoption of advanced bioprocessing techniques, rising demand for biosimilars.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Which Major Drivers Are Strengthening Demand In The Biologics CDMO Market?
The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in March 2024, according to the IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies surged to $5.9 billion in 2023, an increase of 38% from 2022. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market.

How Is The Biologics CDMO Market Divided Across Its Major Segment Categories?
The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Trends Are Reshaping Growth Within The Biologics CDMO Market?
Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.

Which Influential Players Dominate The Competitive Environment Of The Biologics CDMO Market?
Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Get Your In-Depth Biologics CDMO Market Report Now:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Geographic Markets Are Contributing Most Significantly To The Progress Of The Biologics CDMO Market?
North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company